CEO Anders Weilandt presents Chordate Medical at Aktiedagen on May 2nd

On Monday 2 May, 11:00, Chordate's CEO Anders Weilandt will participate on Aktiespararnas event Aktiedagen Stockholm. He will present the latest developments in the company, such as the recently completed first phase of the marketing authorization process in the United States, the upcoming representative office in Saudi Arabia and the marketing efforts in the United Kingdom.

"It is important for us to meet both existing and potential new shareholders. We want to take every opportunity to inform the market and Aktiespararna is an important platform with professional events. They know how to guide their members to good companies and good investments, and it will be extra fun to have a live audience again," says Anders Weilandt, Chordate CEO.

Aktiedagen is a hybrid event that is held for an audience on Operaterassen and livestreamed on Aktiespararna's Youtube channel and on The event is open to everyone and does not require membership in Aktiespararna. No registration is required to follow the event digitally.

Read more about the event and register for the physical event here:

For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277

The following documents can be retrieved from beQuoted

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel, and Saudi Arabia. Chordate Medical's share is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at

Chordate's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB, +46 40 200 250,

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

More press releases

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact